抗体偶联药物联合免疫抑制剂治疗局部晚期或转移性尿路上皮癌的研究进展  

Advances in the treatment of locally advanced or metastatic uroepithelial carcinoma with antibody-coupled drugs combined with immunosuppressive agents

作　　者：邓奇郎 李志刚 李成 刘波佑(综述) 王英磊(审校) DENG Qilang;LI Zhigang;LI Cheng;LIU Boyou;WANG Yinglei(Department of Urology,Yantai Affiliated Hospital of Binzhou Medical University,Yantai,Shandong 264100,China)

机构地区：[1]滨州医学院烟台附属医院泌尿外科,山东烟台264100

出　　处：《现代医药卫生》2024年第19期3353-3358,共6页Journal of Modern Medicine & Health

摘　　要：尿路上皮癌(UC)作为一种泌尿系统常见的恶性肿瘤,其患病人数不断增加,部分患者初治时已发展为无法外科手术的局部晚期或远处转移UC(la/mUC),目前的标准治疗方案是以铂类为基础的化疗,但不良反应和治疗效果并不理想。近年来,抗体偶联药物联合免疫检查点抑制剂治疗策略正逐渐成为癌症精准医疗研究的新焦点,为该类患者带来了新的治疗选择。当前这一领域的相关临床试验取得诸多成果,该文旨在对最近的研究进展进行全面回顾。Urothelial carcinoma(UC),as a common malignant tumor of the urinary system,has an increasing inumber of patients.Some patients have developed into inoperable locally advanced or distant metastatic UC(la/mUC)at the initial treatment.At present,the standard treatment scheme is platinum-based chemotherapy,but the adverse reactions and therapeutic effects are not ideal.In recent years,antibody-drug conjugate combined with immune checkpoint inhibitors has gradually become a new focus of cancer precision medicine research,bringing new treatment options for these patients.Currently,there are many clinical trials in this field,and the purpose of this article was to provide a comprehensive review of the recent research progress.

关 键 词：抗体偶联药物 免疫抑制剂 尿路上皮癌 联合治疗 综述 

分 类 号：R69[医药卫生—泌尿科学]